Ken Griffin Liquidia Corp Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$8.9 - $14.11 $556,250 - $881,875	62,500 Added 174.09%	98,400 $984,000
Q2 2024 Aug 14, 2024	SELL	$11.96 - $15.71 $485,576 - $637,826	-40,600 Reduced 53.07%	35,900 $430,000
Q1 2024 May 15, 2024	BUY	$11.35 - $16.73 $183,870 - $271,026	16,200 Added 26.87%	76,500 $1.13 Million
Q4 2023 Feb 14, 2024	BUY	$5.77 - $12.19 $131,556 - $277,932	22,800 Added 60.8%	60,300 $725,000
Q3 2023 Nov 14, 2023	BUY	$6.27 - $8.15 $72,732 - $94,540	11,600 Added 44.79%	37,500 $237,000
Q2 2023 Aug 14, 2023	SELL	$6.63 - $9.9 $86,853 - $129,690	-13,100 Reduced 33.59%	25,900 $203,000
Q1 2023 May 15, 2023	SELL	$5.72 - $7.91 $60,060 - $83,055	-10,500 Reduced 21.21%	39,000 $269,000
Q4 2022 Feb 14, 2023	SELL	$4.68 - $6.54 $162,864 - $227,592	-34,800 Reduced 41.28%	49,500 $315,000
Q3 2022 Nov 14, 2022	BUY	$3.73 - $8.39 $218,951 - $492,493	58,700 Added 229.3%	84,300 $459,000

171

44.3M

1.55M

1.52M

Ticker LQDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,362,300
Market Cap $685M
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.